Cargando…

Rituximab-induced serum sickness in the treatment of idiopathic membranous nephropathy

We report a case of rituximab-induced serum sickness in a 50-year-old female with idiopathic membranous nephropathy. Presentation was characterized by a widespread rash 1 week after rituximab administration followed by fever and profound haemodynamic instability, mimicking sepsis. Symptoms resolved...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheong, Jamie, Ooi, Khai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Glomerulonephritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5798076/ https://www.ncbi.nlm.nih.gov/pubmed/29423201 http://dx.doi.org/10.1093/ckj/sfx072

Ejemplares similares

Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal
por: Rojas-Rivera, Jorge Enrique, et al.
Publicado: (2019)

Treatment pattern in patients with idiopathic membranous nephropathy—practices in Sweden at the start of the millennium
por: Lönnbro-Widgren, Jennie, et al.
Publicado: (2016)

Idiopathic membranous nephropathy in patients with diabetes mellitus: a diagnostic and therapeutic quandary!
por: Bhadauria, Dharmendra, et al.
Publicado: (2018)

The investigative burden of membranous nephropathy in the UK
por: Hamilton, Patrick, et al.
Publicado: (2019)

Anti-phospholipase A2 receptor antibody and spontaneous remission in membranous nephropathy
por: Diaz, Montserrat, et al.
Publicado: (2018)

Necrotizing and crescentic glomerulonephritis with membranous nephropathy in a patient exposed to levamisole-adulterated cocaine
por: Carrara, Camillo, et al.
Publicado: (2016)

Antiphospholipase 2 receptor antibody levels to predict complete spontaneous remission in primary membranous nephropathy
por: Rodas, Lida M, et al.
Publicado: (2018)

Membranous nephropathy due to chronic mercury poisoning from traditional Indian medicines: report of five cases
por: Doshi, Manan, et al.
Publicado: (2018)

Higher serum galactose-deficient immunoglobulin A1 concentration is associated with stronger mesangial cellular inflammatory response and more severe histologic findings in immunoglobulin A nephropathy
por: Nguyen, Celine, et al.
Publicado: (2018)

Efficacy of mycophenolate treatment in adults with steroid-dependent/frequently relapsing idiopathic nephrotic syndrome
por: Sandoval, Diego, et al.
Publicado: (2017)

IgA nephropathy in Greece: data from the registry of the Hellenic Society of Nephrology
por: Stangou, Maria, et al.
Publicado: (2018)

MicroRNAs: a new avenue to understand, investigate and treat immunoglobulin A nephropathy?
por: Selvaskandan, Haresh, et al.
Publicado: (2018)

Study protocol: responding to the needs of patients with IgA nephropathy, a social media approach
por: Graham-Brown, Matthew P M, et al.
Publicado: (2018)

Azithromycin suppressed relapses of idiopathic nephrotic syndrome in a child
por: Hara, Hiromichi, et al.
Publicado: (2018)

Atypical anti-glomerular basement membrane disease
por: Troxell, Megan L., et al.
Publicado: (2016)

Rapidly progressive glomerulonephritis due to coexistent anti-glomerular basement membrane disease and fibrillary glomerulonephritis
por: Cheungpasitporn, Wisit, et al.
Publicado: (2016)

Atypical anti-glomerular basement membrane disease presenting as macroscopic haematuria, loin pain and acute kidney injury after intensive exercise
por: Le Flecher, Arnaud, et al.
Publicado: (2019)

Efficacy and safety of adrenocorticotropic hormone treatment in glomerular diseases: a systematic review and meta-analysis
por: Kittanamongkolchai, Wonngarm, et al.
Publicado: (2016)

Membranoproliferative glomerulonephritis and C3 glomerulopathy in children: change in treatment modality? A report of a case series
por: Spartà, Giuseppina, et al.
Publicado: (2018)

Comparing outcomes of biopsy-proven anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis patients treated with cyclophosphamide in the 20th and 21st centuries: a 23-year study
por: Whatmough, Steven, et al.
Publicado: (2018)

Minimal change disease and malaria
por: Rangwani, Neil, et al.
Publicado: (2018)

Continuous B-cell depletion in frequently relapsing, steroid-dependent and steroid-resistant nephrotic syndrome
por: Cortazar, Frank B, et al.
Publicado: (2018)

Post-streptococcal glomerulonephritis associated with atypical hemolytic uremic syndrome: to treat or not to treat with eculizumab?
por: Kakajiwala, Aadil, et al.
Publicado: (2016)

Clinical factors influencing the decision to transfuse after percutaneous native kidney biopsy
por: Whittier, William L., et al.
Publicado: (2016)

Minimal change disease onset observed after bevacizumab administration
por: Hanna, Ramy M., et al.
Publicado: (2016)

Post-infectious glomerulonephritis with crescents in adults: a retrospective study
por: Baikunje, Shashidhar, et al.
Publicado: (2016)

Therapeutic variability in adult minimal change disease and focal segmental glomerulosclerosis
por: Fernandez-Juarez, Gema, et al.
Publicado: (2016)

Revisiting post-infectious glomerulonephritis in the emerging era of C3 glomerulopathy
por: Khalighi, Mazdak A., et al.
Publicado: (2016)

Treatment with rituximab in idiopathic membranous nephropathy
por: Fiorentino, Marco, et al.
Publicado: (2016)

Recurrent focal segmental glomerulosclerosis apparently resistant to plasmapheresis improves after surgical repair of arteriovenous fistula aneurysms
por: Ding, Yanli, et al.
Publicado: (2016)

Kidney transplant outcomes in familial C3 glomerulopathy
por: Wong, Limy, et al.
Publicado: (2016)

WCN23-0542 SARS-COV2 ASSOCIATED MINIMAL CHANGE GLOMERULONEPHRITIS LONG-TERM EFFECTS
por: Akl, A.I., et al.
Publicado: (2023)

Two cases of idiopathic membranous nephropathy treated with rituximab
por: Young Yoon, Jae, et al.
Publicado: (2013)

Efficacy and Safety of Rituximab in the Treatment of Idiopathic Membranous Nephropathy: A Meta-Analysis
por: Lu, Huijuan, et al.
Publicado: (2022)

Rituximab in Membranous Nephropathy
por: Gauckler, Philipp, et al.
Publicado: (2021)

Treatment of rituximab in patients with idiopathic membranous nephropathy: a case series and literature review
por: Jeon, Soo-Jee, et al.
Publicado: (2022)

Retracted: Efficacy and Safety of Rituximab in the Treatment of Idiopathic Membranous Nephropathy: A Meta-Analysis
por: and Biomechanics, Applied Bionics
Publicado: (2023)

Rituximab: Serum sickness: case report
Publicado: (2020)

Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience
por: Chen, Ping, et al.
Publicado: (2023)

Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience
por: Bagchi, Soumita, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9v6tf3avqae719jchgiera009l